IP Library Granted Patent US 10,620,196
Granted Patent B2
US 10,620,196 · App. 15/158,901 · Granted Apr 14, 2020

Assays for detecting analytes in samples and kits and compositions related thereto

Inventors: Rajesh K. Mehra (Union City, CA); Kenneth P. Aron (Union City, CA)
Assignee: ABAXIS, INC.
G01N33/54313G01N33/542G01N33/54346G01N33/569G01N2333/015G01N2333/15G01N2333/20G01N2333/29G01N2333/43526G01N2333/44G01N2333/4712G01N2333/4737
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,620,196
App. No.
15/158,901
Granted
Apr 14, 2020
Kind
B2
Abstract

The present invention provides methods of detecting analytes using particles having different physico-chemical properties, such as buoyancy, size, density, spectral characteristics, and/or binding properties, in solution-based sandwich assays and solution-based competition assays. The methods can be performed using rotors and bench-top centrifuges and provide for rapid, qualitative and quantitative detection of analytes. The present invention also provides kits that can be used to perform the methods, and mixtures containing particles suitable for the methods.

Claims (18)

1. A method of detecting an analyte in a sample comprising

mixing a sample with a population of first particles and a population of second particles to form a suspension, wherein the first and second particles are different and capable of forming a multi-particle complex comprising the first particle, second particle, and the analyte,

removing the multi-particle complexes from the suspension, and

detecting the presence of free first particles in the suspension after removal of the multi-particle complexes,

wherein a decrease of the free first particles in the suspension is indicative of the presence of the analyte in the sample.

2. The method of claim 1 , wherein the first particles or second particles comprise an antibody, antigen, polypeptide, polynucleotide, nucleoprotein, or aptamer.

3. The method of claim 1 , wherein the first particles comprise a first monoclonal antibody or a first polyclonal antibody recognizing a first epitope on the analyte, wherein the second particles comprise a second monoclonal antibody or a second polyclonal antibody recognizing a second epitope on the analyte, and wherein the first epitope does not overlap with the second epitope.

4. The method of claim 1 , wherein the first particles are colloidal nanoparticles, nanotubes, hollow nanospheres, or core-shell structures that comprise gold, silver, platinum, copper, or a composite of any of the foregoing metals.

5. The method of claim 1 , wherein the free first particles remain in suspension at centrifugal forces of about 1600 g or less.

6. The method of claim 1 , wherein the first particles are smaller than the second particles.

7. The method of claim 1 , wherein the first particles are colloidal nanoparticles, nanotubes, hollow nanospheres, or core-shell structures that comprise gold, silver, platinum, copper, or a composite of any of the foregoing metals, and wherein the second particles comprise latex, polystyrene, polycarbonate, polyvinylidene fluoride (PVDF), or silica.

8. The method of claim 1 , wherein the free first particles remain in suspension at centrifugal forces of about 1600 g or less, and wherein free second particles sediment out of the suspension at centrifugal forces of about 1000 g to about 1600 g.

9. The method of claim 1 , wherein the first particles have an average diameter of about 5 nm to about 40 nm, and wherein the second particles have an average diameter of about 400 nm to about 2000 nm.

10. The method of claim 1 , wherein the sample is in a liquid form and wherein the population of first particles and the population of second particles are in solid form prior to the mixing.

11. The method of claim 1 , wherein the analyte is canine heartworm, feline leukemia virus, canine parvovirus, C-reactive protein, Giardia lamblia, Ehrlichia antigen or antibody, Borrelia antigen or antibody, and cardiac marker antigens.

12. The method of claim 1 , wherein removing the multi-particle complexes comprises using centrifugal force.

13. The method of claim 1 , wherein the population of first particles and the population of second particles are separate prior to mixing with the sample.

14. The method of claim 1 , wherein the ratio of the average diameter of second particles to the average diameter of first particles is about 5:1 to about 50:1.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2021
From: ABAXIS LLC
To: ZOETIS SERVICES LLC
Reel/Frame 055474/0599 →
CHANGE OF NAME Recorded Mar 3, 2021
From: ABAXIS, INC.
To: ABAXIS LLC
Reel/Frame 055474/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2016
From: MEHRA, RAJESH K.; ARON, KENNETH P.
To: ABAXIS, INC.
Reel/Frame 038645/0676 →
Continuity (3)
Continuation 12971968 · Dec 17, 2010
Provisional Application 61287637 · Dec 17, 2009
Related Publication 20170108494A1 · Apr 20, 2017